Shandong Sito Bio-technology Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100002F36
CNY
12.06
0.48 (4.15%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Shandong Sito Bio-technology Co., Ltd.

Why is Shandong Sito Bio-technology Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 1.65%
  • The company has been able to generate a Return on Capital Employed (avg) of 1.65% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of 2.45% and Operating profit at 12.66% over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 1.52% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 2.45% and Operating profit at 12.66% over the last 5 years
4
With a growth in Net Sales of 26.24%, the company declared Very Positive results in Mar 26
  • The company has declared positive results for the last 2 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at CNY 199.55 MM
  • PRE-TAX PROFIT(Q) Highest at CNY 3.97 MM
  • NET PROFIT(Q) Highest at CNY 3.62 MM
5
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -30.03%, its profits have risen by 64.9%
  • At the current price, the company has a high dividend yield of 0.2
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Shandong Sito Bio-technology Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shandong Sito Bio-technology Co., Ltd. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Shandong Sito Bio-technology Co., Ltd.
-28.51%
-0.26
30.85%
China Shanghai Composite
23.91%
1.73
13.79%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
2.45%
EBIT Growth (5y)
12.66%
EBIT to Interest (avg)
-0.06
Debt to EBITDA (avg)
5.40
Net Debt to Equity (avg)
0.35
Sales to Capital Employed (avg)
0.39
Tax Ratio
2.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.65%
ROE (avg)
1.52%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.15
EV to EBIT
-101.27
EV to EBITDA
46.36
EV to Capital Employed
1.11
EV to Sales
2.47
PEG Ratio
NA
Dividend Yield
0.16%
ROCE (Latest)
-1.10%
ROE (Latest)
-2.73%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

29What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 199.55 MM

PRE-TAX PROFIT(Q)

Highest at CNY 3.97 MM

NET PROFIT(Q)

Highest at CNY 3.62 MM

RAW MATERIAL COST(Y)

Fallen by -400.71% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.91 times

NET SALES(Q)

Highest at CNY 328.05 MM

EPS(Q)

Highest at CNY 0.02

0What is not working for the Company
NO KEY NEGATIVE TRIGGERS

Here's what is working for Shandong Sito Bio-technology Co., Ltd.

Operating Cash Flow
Highest at CNY 199.55 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit
Highest at CNY 3.97 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Pre-Tax Profit
At CNY 3.97 MM has Grown at 112.21%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 3.62 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Profit
At CNY 3.62 MM has Grown at 113.15%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales
Highest at CNY 328.05 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Net Sales
At CNY 328.05 MM has Grown at 26.24%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

EPS
Highest at CNY 0.02
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Inventory Turnover Ratio
Highest at 1.91 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -400.71% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales